FAKTOR OPTIONSSCHEIN - GILEAD SCIENCES | Delayed Deutsche Boerse AG 04:13:53 2024-06-03 am EDT | ||
| 4.64 EUR | -6.45% |
|
| 1 month | +7.83% | ||
| 3 months | +52.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-03 | 4.64 | -6.45% |
| 24-05-31 | 4.96 | +4.86% |
| 24-05-30 | 4.73 | -5.96% |
| 24-05-29 | 5.03 | +4.57% |
| 24-05-28 | 4.81 | +13.98% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 04:13 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | UBS |
| WKN | UK7RA9 |
| ISIN | DE000UK7RA95 |
| Date issued | 2022-11-01 |
| Strike | 80.1 $ |
| Maturity | Unlimited |
| Parity | 3.04 : 1 |
| Emission price | 4.82 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.35 € |
|---|---|
| Lowest since issue | 1.67 € |
| Spread | 0.3 € |
| Spread % | 6.07% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.27
USD
Average target price
82.7
USD
Spread / Average Target
+28.67%
- Stock Market
- Certificates
- Certificat
